Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anixa Biosciences, Inc. - Common Stock (NQ:ANIX)

2.850 -0.030 (-1.04%)
Streaming Delayed Price Updated: 9:41 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,751
Open 2.870
Bid (Size) 2.790 (300)
Ask (Size) 2.910 (400)
Prev. Close 2.880
Today's Range 2.850 - 2.970
52wk Range 2.331 - 5.457
Shares Outstanding 33,376,690
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa’s T-Cell Innovations Show Breakthrough Potential in Solid Tumors”
January 21, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Anixa Biosciences, Inc. (NASDAQ: ANIX) titled, “Anixa’s T-Cell... 
Via TheNewswire.com
News headline image
3 Under-the-Radar Biotechs Under $5 That Could Soar 200% ↗
3 biotech stocks under $5 with cancer, obesity, and psychedelic therapies offer speculative investors high-risk, high-reward potential: HOTH, SILO, and ANIX. 
Via MarketBeat

Performance

YTD
-9.8%
-9.8%
1 Month
-8.4%
-8.4%
3 Month
-30.5%
-30.5%
6 Month
-4.0%
-4.0%
1 Year
-5.6%
-5.6%

More News

Read More
News headline image
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent ↗
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Recap: Anixa Biosciences Q1 Earnings ↗
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines ↗
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine ↗
Via Benzinga
Topics Intellectual Property
News headline image
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗
Via Benzinga
News headline image
iAccess Alpha's Buyside Best Ideas Virtual Winter Conference December 10-11, 2024
Via ACCESSWIRE
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying ↗
Via Benzinga
News headline image
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy ↗
Via Benzinga
News headline image
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program ↗
Via Benzinga
News headline image
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024 ↗
Via InvestorPlace
News headline image
7 Penny Biotech Stocks to Triple Your Investment ↗
Via InvestorPlace
Anixa Biosciences, Inc. (NASDAQ: ANIX) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
News headline image
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Via AB Newswire
News headline image
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Via ACCESSWIRE
News headline image
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape? ↗
Via Benzinga
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 ↗
Via InvestorPlace
News headline image
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations' ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
The 3 Most Undervalued Cheap Stocks to Buy in September 2023 ↗
Via InvestorPlace
News headline image
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via ACCESSWIRE

Frequently Asked Questions

Is Anixa Biosciences, Inc. - Common Stock publicly traded?
Yes, Anixa Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Anixa Biosciences, Inc. - Common Stock trade on?
Anixa Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anixa Biosciences, Inc. - Common Stock?
The ticker symbol for Anixa Biosciences, Inc. - Common Stock is ANIX on the Nasdaq Stock Market
What is the current price of Anixa Biosciences, Inc. - Common Stock?
The current price of Anixa Biosciences, Inc. - Common Stock is 2.850
When was Anixa Biosciences, Inc. - Common Stock last traded?
The last trade of Anixa Biosciences, Inc. - Common Stock was at 02/18/26 09:41 AM ET
What is the market capitalization of Anixa Biosciences, Inc. - Common Stock?
The market capitalization of Anixa Biosciences, Inc. - Common Stock is 95.12M
How many shares of Anixa Biosciences, Inc. - Common Stock are outstanding?
Anixa Biosciences, Inc. - Common Stock has 95M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.